A national research study that is currently seeking participants offers an opportunity for people to contribute to the science about how to effectively treat monkeypox infection.

What’s the study all about?

The NIH National Institute for Allergy and Infectious Diseases has launched the Study of Tecovirimat for Human Monkeypox Virus (STOMP). Led by the AIDS Clinical Trials GroupExit Disclaimer (ACTG), STOMP is a phase 3 clinical trial to evaluate the effectiveness of the antiviral drug tecovirimat, also known as TPOXX, for the treatment of human monkeypox infection.

This trial will enroll more than 500 adults with severe monkeypox and those at high risk of severe disease, including pregnant and breastfeeding people, children, and individuals with severe immune deficiency and active inflammatory skin conditions. These participants will all receive open-label TPOXX. Other adult participants—530 in total—will be randomly assigned in a 2:1 ratio to receive TPOXX or placebo pills. The trial is double-blind, meaning neither participants nor investigators will know who is receiving placebo or TPOXX. Investigators will gather data to determine if participants receiving TPOXX heal more quickly and have less pain compared with those taking placebo.

Individuals and organizations can help spread the word about how people can get involved.

Who is eligible to participate in the study?

Adults and children of any age who have monkeypox are eligible to enroll in the STOMP trial. You must have presumed or confirmed monkeypox infection (testing positive within seven days) and started experiencing symptoms within 13 days.

How can I find a research site?

STOMP sites are located across the country. You can visit this map of clinical trial sitesExit Disclaimer to find one near you or contact the STOMP call center at 1-855-876-9997 for more information

Learn more about STOMPExit Disclaimer.